Serum soluble CD30 in early arthritis: A sign of inflammation but not a predictor of outcome

Clinical and Experimental Rheumatology

Volumn 26, Issue 5, 2008, Pages 922-925

  Savolainen, Elina ^a   Matinlauri, Irma ^b   Kautiainen, Hannu ^d   Luosujärvi, Riitta ^e   Kaipiainen Seppänen, Oili ^c  

^a Kuopio Municipal Hospital   (Finland)

^b Department of Clinical Chemistry ^*  (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d Medcare Foundation   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Remission; Rheumatoid arthritis; sCD30; T cell activation; Undifferentiated arthritis

Indexed keywords

CD30 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

AGED; ANTIGENS, CD30; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; REMISSION INDUCTION; ROC CURVE;

EID: 57249108544     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. + T cells in rheumatoid synovitis:mEchanisms of recruitment and functional role. J Immunol 2000; 164: 4399-407.
2. + T cells in rheumatoid arthritis. Acta Med Okayama 2003; 57: 267-77.
3. VAN DER GRAAF WL, PRINS APA, DIJKMANS BAC: Prognostic value of Th1/ Th2 ratio in rheumatoid arthritis. Lancet 1998; 351: 1931.
4. GERLI R, BISTONI O, LUNARDI C et al.: Soluble CD 30 in early rheumatoid arthritis as a predictor of good response to secondline therapy. Rheumatology 1999; 38: 1282-4.
5. SAVOLAINEN E, KAIPIAINEN-SEPPÄNEN O, KRÖGER L, LUOSUJÄRVI R: Total incidence and distribution of inflammatory joint diseases in a defined population: Results from the Kuopio 2000 Arthritis Survey. J Rheumatol 2003; 30: 2460-8.
6. SAVOLAINEN E, KAUTIAINEN H, KOIVULA MK, LUOSUJÄRVI R, RISTELI J, KAIPIAINEN-SEPPÄNEN O: Change of diagnoses and outcome of patients with early inflammatory joint diseases during a mean 13 month follow up. Scand J Rheumatol 2007; 36: 194-7.
7. PINALS RS, MASI AT, LARSEN RA: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
8. CONOVER WJ, IMAN R: Analysis of covariance using the rank transformation. Biometrics 1982; 38: 715-24.
9. WANG G, HANSEN H, TATSIS E, CSERNOK E, LEMKE H, GROSS L: High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am J Med 1997; 102: 517-23.
10. LESOURD BM, MEAUME S: Cell mediated immunity changes in ageing, relative importance of cell subpopulation switches and of nutritional factors. Immunology Letters 1994; 40: 235-42.
11. KRAMPERA M, VINANTE F, TAVECCHIA L et al.: Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999; 117: 291-7.
12. HANEKOM WA, HUSSEY GD, HUGHES EJ, POTGIETER S, YOGEV R, CHECK IJ: Plasmasoluble CD30 in childhood tuberculosis: Effects of disease severity, nutritional status, and vitamin A therapy. Clin Diagn Lab Immunol 1999; 6: 204-8.
13. SÜSAL C, PELZL S, DOHLER B, OPELZ G: Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650-6.